Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free ENTX Stock Alerts

Entera Bio (ENTX) Competitors

Entera Bio logo
$1.16 +0.05 (+4.50%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 0.00 (0.00%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ENTX vs. ACB, WHWK, CRBU, NKTX, and CNTN

Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Aurora Cannabis (ACB), Whitehawk Therapeutics (WHWK), Caribou Biosciences (CRBU), Nkarta (NKTX), and Hillstream Biopharma (CNTN). These companies are all part of the "pharmaceutical products" industry.

How does Entera Bio compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

In the previous week, Entera Bio had 5 more articles in the media than Aurora Cannabis. MarketBeat recorded 7 mentions for Entera Bio and 2 mentions for Aurora Cannabis. Entera Bio's average media sentiment score of 1.16 beat Aurora Cannabis' score of 0.25 indicating that Entera Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Entera Bio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 10.4% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Entera Bio has a consensus price target of $9.00, indicating a potential upside of 675.86%. Given Entera Bio's higher possible upside, analysts plainly believe Entera Bio is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Entera Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Aurora Cannabis has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.

Entera Bio has a net margin of 0.00% compared to Aurora Cannabis' net margin of -23.46%. Aurora Cannabis' return on equity of -0.04% beat Entera Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-23.46% -0.04% -0.03%
Entera Bio N/A -66.39%-57.77%

Aurora Cannabis has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$246.72M0.82$1.63M-$1.08N/A
Entera Bio$40K1,351.98-$11.44M-$0.26N/A

Summary

Entera Bio beats Aurora Cannabis on 8 of the 13 factors compared between the two stocks.

How does Entera Bio compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Entera Bio (NASDAQ:ENTX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

In the previous week, Entera Bio had 5 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 7 mentions for Entera Bio and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Entera Bio's score of 1.16 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Whitehawk Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Entera Bio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 10.4% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Whitehawk Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.

Entera Bio has lower revenue, but higher earnings than Whitehawk Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Whitehawk Therapeutics$7.14M29.15-$20.60M$0.478.96
Entera Bio$40K1,351.98-$11.44M-$0.26N/A

Whitehawk Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 66.27%. Entera Bio has a consensus price target of $9.00, indicating a potential upside of 675.86%. Given Entera Bio's higher probable upside, analysts plainly believe Entera Bio is more favorable than Whitehawk Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Entera Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Whitehawk Therapeutics' return on equity of -62.88% beat Entera Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Whitehawk TherapeuticsN/A -62.88% -58.98%
Entera Bio N/A -66.39%-57.77%

Summary

Whitehawk Therapeutics beats Entera Bio on 8 of the 14 factors compared between the two stocks.

How does Entera Bio compare to Caribou Biosciences?

Entera Bio (NASDAQ:ENTX) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Entera Bio has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.

Entera Bio has higher earnings, but lower revenue than Caribou Biosciences. Entera Bio is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entera Bio$40K1,351.98-$11.44M-$0.26N/A
Caribou Biosciences$11.16M17.07-$148.12M-$1.59N/A

Entera Bio has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,327.40%. Entera Bio's return on equity of -66.39% beat Caribou Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Entera BioN/A -66.39% -57.77%
Caribou Biosciences -1,327.40%-78.40%-58.68%

Entera Bio currently has a consensus price target of $9.00, indicating a potential upside of 675.86%. Caribou Biosciences has a consensus price target of $8.00, indicating a potential upside of 314.51%. Given Entera Bio's higher possible upside, equities research analysts clearly believe Entera Bio is more favorable than Caribou Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entera Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

In the previous week, Entera Bio had 4 more articles in the media than Caribou Biosciences. MarketBeat recorded 7 mentions for Entera Bio and 3 mentions for Caribou Biosciences. Entera Bio's average media sentiment score of 1.16 beat Caribou Biosciences' score of 0.00 indicating that Entera Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Entera Bio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Caribou Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Entera Bio beats Caribou Biosciences on 10 of the 16 factors compared between the two stocks.

How does Entera Bio compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Entera Bio has higher revenue and earnings than Nkarta. Entera Bio is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/A-$104.08M-$1.40N/A
Entera Bio$40K1,351.98-$11.44M-$0.26N/A

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 8.4% of Nkarta shares are owned by insiders. Comparatively, 10.4% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nkarta has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.

Nkarta's return on equity of -30.02% beat Entera Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
NkartaN/A -30.02% -23.78%
Entera Bio N/A -66.39%-57.77%

In the previous week, Entera Bio had 5 more articles in the media than Nkarta. MarketBeat recorded 7 mentions for Entera Bio and 2 mentions for Nkarta. Entera Bio's average media sentiment score of 1.16 beat Nkarta's score of 0.34 indicating that Entera Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nkarta
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Entera Bio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nkarta currently has a consensus target price of $11.33, indicating a potential upside of 267.97%. Entera Bio has a consensus target price of $9.00, indicating a potential upside of 675.86%. Given Entera Bio's higher possible upside, analysts plainly believe Entera Bio is more favorable than Nkarta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nkarta
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Entera Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Entera Bio beats Nkarta on 8 of the 13 factors compared between the two stocks.

How does Entera Bio compare to Hillstream Biopharma?

Entera Bio (NASDAQ:ENTX) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Entera Bio presently has a consensus target price of $9.00, suggesting a potential upside of 675.86%. Given Entera Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Entera Bio is more favorable than Hillstream Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entera Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Hillstream Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Entera Bio has higher revenue and earnings than Hillstream Biopharma. Entera Bio is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entera Bio$40K1,351.98-$11.44M-$0.26N/A
Hillstream BiopharmaN/AN/A-$35.92M-$3.99N/A

Entera Bio has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Hillstream Biopharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 10.4% of Entera Bio shares are held by company insiders. Comparatively, 6.7% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Hillstream Biopharma's return on equity of -35.59% beat Entera Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Entera BioN/A -66.39% -57.77%
Hillstream Biopharma N/A -35.59%-27.05%

In the previous week, Entera Bio had 7 more articles in the media than Hillstream Biopharma. MarketBeat recorded 7 mentions for Entera Bio and 0 mentions for Hillstream Biopharma. Entera Bio's average media sentiment score of 1.16 beat Hillstream Biopharma's score of 0.00 indicating that Entera Bio is being referred to more favorably in the media.

Company Overall Sentiment
Entera Bio Positive
Hillstream Biopharma Neutral

Summary

Entera Bio beats Hillstream Biopharma on 11 of the 13 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTX vs. The Competition

Export
MetricEntera BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$51.75M$3.39B$6.24B$11.86B
Dividend YieldN/A2.20%2.73%5.21%
P/E RatioN/A38.8529.0428.48
Price / Sales1,351.98157.28477.1060.43
Price / CashN/A57.8827.6236.52
Price / Book4.007.039.676.67
Net Income-$11.44M$23.62M$3.55B$332.64M
7 Day Performance2.65%3.67%1.70%2.01%
1 Month Performance-7.94%7.17%5.62%9.19%
1 Year Performance-49.34%67.04%34.42%39.59%

Entera Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTX
Entera Bio
3.4446 of 5 stars		$1.16
+4.5%		$9.00
+675.9%		N/A$51.75M$40KN/A20
ACB
Aurora Cannabis
0.7825 of 5 stars		$3.45
-1.9%		N/AN/A$203.63M$246.72MN/A1,130
WHWK
Whitehawk Therapeutics
4.0714 of 5 stars		$4.23
+1.7%		$7.00
+65.5%		N/A$200.59M$7.15M9.0421
CRBU
Caribou Biosciences
1.8688 of 5 stars		$2.08
-2.6%		$8.00
+285.5%		N/A$200.53M$11.16MN/A100
NKTX
Nkarta
2.8159 of 5 stars		$2.79
-1.3%		$11.33
+305.8%		N/A$199.11MN/AN/A140

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENTX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel